Performances in N.Y.C. Advertisement Supported by Daphne Rubin-Vega stars as a laid-off office worker who spins into a murderous rage in this update of Elmer L. Rice’s 1923 classic. By Laura ...

Emily Long is a freelance writer based in Salt Lake City. After graduating from Duke University, she spent several years reporting on the federal workforce for Government Executive, a publication of ...

This is read by an automated voice. Please report any issues or inconsistencies here. It’s a good time for Elmer Rice’s “The Adding Machine,” which can only mean that it’s once again a bad time for ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

When I see a call coming in from a number I don’t recognize, my first instinct is to ignore it. But since I have kids, I need to pick up that phone call if it's from my area code in the off chance ...

Upcoming film “Number One” has unveiled new stills of Gong Seung Yeon in character! “Number One” follows Ha Min (Choi Woo Shik), who one day begins seeing a number that drops by one every time he eats ...

Welcome to this week's Chutes & Ladders, our roundup of significant leadership hirings, firings and retirings across the industry. Please send the good word—or the bad—from your shop to Darren ...

For example, Nvidia owns stakes in six smaller companies. I think Recursion Pharmaceuticals (RXRX 3.62%) is arguably the most intriguing of the group. Recursion looks like a big dud so far. The ...

Recursion Pharmaceuticals trades at a $2.65bn valuation despite slow clinical progress, high cash burn, and no late-stage assets. RXRX's AI-driven drug discovery model is ambitious, but pipeline value ...

In AI research, progress is often equated with size. But a small team at Samsung’s AI lab in Montreal has taken another approach that is proving to show great promise. Their new Tiny Recursive Model ...